Molecular and cellular mechanisms of GLP-1 receptor agonists and their emerging clinical applications
References
- Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front Public Health. 2025;13:15;DOI:10.3389/fpubh.2025.1515797.
- Rangraze I, Patoulias D, Karakasis P, El-Tanani M, Rizzo M. Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era? Expert Rev Clin Pharmacol. 2024;17(8):853-6; DOI:10.1080/17512433.2024.2408753.
- Ghemrawi R, Battaglia-Hsu SF, Arnold C. Endoplasmic reticulum stress in metabolic disorders. Cells. 2018;7(6):63; DOI:10.3390/cells7060063.
- Gorgojo-Martínez JJ. Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus. J Clin Med. 2025;14(3):678; DOI:10.3390/jcm14030678.
- Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tscho p MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130;DOI:10.1016/j.molmet.2019.09.010.
- Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10):1780-95; DOI:10.1007/s00125-023-05956-x.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;3:27(4):740–56; DOI:10.1016/J.CMET.2018.03.001.
- Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217-27; DOI:10.1172/JCI97233.
- Yap MKK, Misuan N. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant. Basic Clin Pharmacol Toxicol. 2019;124(5):513-27; DOI:10.1111/bcpt.13169.
- Sofogianni A, Tziomalos K. Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review. Adv Ther. 2020;37:4165-74; DOI:10.1007/s12325-020-01478-9.
- Pahud de Mortanges A, Sinaci E, Salvador D, Bally L, Muka T, Wilhelm M, Bano A. GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events. Front Pharmacol. 2022;13:856111; DOI:10.3389/fphar.2022.856111.
- Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol. 2018;9:672; DOI:10.3389/fendo.2018.00672.
- Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol. 2021;12:721135; DOI:10.3389/fendo.2021.721135.
- Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Trans-duct Target Ther. 2024;9(1):234; DOI:10.1038/s41392-024-01931-z.
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102; DOI:10.1016/j.molmet.2020.101102.
- Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee C Bin, Bae SK. A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Des Devel Ther. 2025;19:3509-37; DOI:10.2147/DDDT. S506957.
- Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans. Diabetes. 2011;60(5):1561-5; DOI:10.2337/DB10-0474.
- Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther. 2015;6(3):239-56; DOI:10.1007/s13300-015-0127-x.
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155; DOI:10.3389/fendo.2019.00155.
- Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657-72; DOI:10.1007/s40262-015-0343-6.
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80; DOI:10.1021/acs. jmedchem.5b00726.
- Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 2024;18:2555-70; DOI:10.2147/DDDT.S470826.
- Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14; DOI:10.1016/j.molmet.2018.09.009.
- Nauck MA, D‘Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169; DOI:10.1186/s12933-022-01604-7.
- Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024;13(3):494-503; DOI:10.1002/psp4.13099.
- Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Penã A. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet. 2016;55(5):625-34; DOI:10.1007/s40262-015-0338-3.
- Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Diabetes Technol Ther. 2020;22(1):10-8; DOI:10.1089/dia.2019.0185.
- Overgaard R V., Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021;60(10):1335-48; DOI:10.1007/s40262-021-01025-x.
- Austin G, Tomas A. Signaling architecture of the glucagon-like peptide-1 receptor. J Clin Invest. 2026;136(2):194752; DOI:10.1172/JCI194752.
- Lymperopoulos A, Altsman VL, Stoicovy RA. Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally Gs Protein-Selective GPCR. Int J Mol Sci. 2025;26(15):7239; DOI:10.3390/IJMS26157239.
- Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21; DOI:10.1111/DOM.13129.
- Marzook A, Tomas A, Jones B. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Front Endocrinol (Lausanne). 2021;12:678055; DOI:10.3389/FENDO.2021.678055.
- Islam MS. Ryanodine Receptors in Islet Cell Function: Calcium Signaling, Hormone Secretion, and Diabetes. Cells. 2025;14(10):690; DOI:10.3390/CELLS14100690.
- Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000;2(11):805-11; DOI:10.1038/35041046.
- Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, Zhang C, Tamamoto A, Satoh T, Miyazaki JI, Seino S. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104(49):19333-8; DOI:10.1073/PNAS.0707054104.
- Gauthier BR, Wollheim CB. Synaptotagmins bind calcium to release insulin. Am J Physiol Endocrinol Metab. 2008;295(6):E1279-86; DOI:10.1152/AJPENDO.90568.2008.
- Gaisano HY. Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis. Diabetes Obes Metab. 2017;19:115-23; DOI:10.1111/DOM.13001.
- Stožer A, Leitgeb EP, Pohorec V, Dolenšek J, Bombek LK, Gosak M, Klemen MS. The Role of cAMP in Beta Cell Stimulus–Secretion and Inter-cellular Coupling. Cells. 2021;10(7):1658; DOI:10.3390/cells10071658.
- Lee JH, Wen X, Cho H, Koo SH. CREB/CRTC2 controls GLP-1-dependent regulation of glucose homeostasis. FASEB J. 2018;32(3):1566-78; DOI:10.1096/FJ.201700845R.
- Kim MJ, Kang JH, Park YG, Ryu GR, Ko SH, Jeong IK, Koh KH, Rhie DJ, Yoon SH, Hahn SJ, Kim MS, Jo YH. Exendin-4 induction of cyclin D1 expression in INS-1 β-cells: involvement of cAMP-responsive element. J Endocrinol. 2006;188(3):623-33; DOI:10.1677/joe.1.06480.
- Van de Velde S, Wiater E, Tran M, Hwang Y, Cole PA, Montminy M. CREB Promotes Beta Cell Gene Expression by Targeting Its Coactivators to Tissue-Specific Enhancers. Mol Cell Biol. 2019;39(17):e00200-19; DOI:10.1128/MCB.00200-19.
- Cunha DA, Ladrie re L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL, Cnop M. Glucagon-Like Peptide-1 Agonists Protect Pancreatic β-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB. Diabetes. 2009;58(12):2851-62; DOI:10.2337/DB09-0685.
- Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48(7):1339-49; DOI:10.1007/s00125-005-1787-2.
- Sacco F, Seelig A, Humphrey SJ, Krahmer N, Volta F, Reggio A, Marchetti P, Gerdes J, Mann M. Phosphoproteomics Reveals the GSK3-PDX1 Axis as a Key Pathogenic Signaling Node in Diabetic Islets. Cell Metab. 2019;29(6):1422-1432.e3; DOI:10.1016/j.cmet.2019.02.012.
- Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol. 2022;179(4):584-99; DOI:10.1111/BPH.15603.
- Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4. Endocrinology. 2011;152(8):3103; DOI:10.1210/en.2011-0174.
- Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15; DOI:10.1210/CLINEM/DGAE719.
- Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilva sy-Szabo A, Willenbrock H, Secher A, Knudsen LB. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2021;5(6):133429; DOI:10.1172/JCI. INSIGHT.133429.
- Holt MK, Richards JE, Cook DR, Brierley DI, Williams DL, Reimann F, Gribble FM, Trapp S. Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food. Diabetes. 2019;68(1):21-33; DOI:10.2337/DB18-0729.
- Hisadome K, Reimann F, Gribble FM, Trapp S. Leptin Directly Depolarizes Preproglucagon Neurons in the Nucleus Tractus Solitarius: Electrical Properties of Glucagon-Like Peptide 1 Neurons. Diabetes. 2010;59(8):1890; DOI:10.2337/DB10-0128.
- Wan W, Qin Q, Xie L, Zhang H, Wu F, Stevens RC, Liu Y. GLP-1R Signaling and Functional Molecules in Incretin Therapy. Molecules. 2023;28(2):751; DOI:10.3390/molecules28020751.
- Ma X, Bruning J, Ashcroft FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci. 2007;27(27):7125-9; DOI:10.1523/JNEUROSCI.1025-07.2007.
- Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäfer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Knudsen LB. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-88; DOI:10.1172/JCI75276.
- He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, Dong Y, Sun J, Guo H, Williams KW. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons – Implications for energy balance and glucose control. Mol Metab. 2019;28:120-34; DOI:10.1016/J.MOLMET.2019.07.008.
- Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake. Endocrinology. 2012;153(2):647-58; DOI:10.1210/EN.2011-1443.
- Mietlicki-Baase EG, Ortinski PI, Reiner DJ, Sinon CG, McCutcheon JE, Pierce RC, Roitman MF, Hayes MR. Glucagon-Like Peptide-1 Receptor Activation in the Nucleus Accumbens Core Suppresses Feeding by Increasing Glutamatergic AMPA/Kainate Signaling. J Neurosci. 2014;34(20):6985; DOI:10.1523/JNEUROSCI.0115-14.2014.
- Wang XF, Liu JJ, Xia J, Liu J, Mirabella V, Pang ZP. Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons. Cell Rep. 2015;12(5):726-33; DOI:10.1016/J.CELREP.2015.06.062.
- Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and In-cretin-Based Therapies on Gastrointestinal Motor Function. J Diabetes Res. 2011;2011(1):279530; DOI:10.1155/2011/279530.
- Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut. 2000;46(5):622; DOI:10.1136/GUT.46.5.622.
- Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50(3):341-8; DOI:10.1136/gut.50.3.341.
- Imeryüz N, Yeğen BÇ, Bozkurt A, Coşkun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4):G920-6; DOI:10.1152/ajpgi.1997.273.4.g920.
- Rotondo A, Amato A, Lentini L, Baldassano S, Mul F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides (NY). 2010;32(1):60-4; DOI:10.1016/J.PEPTIDES.2010.09.028.
- Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglu-tide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-9; DOI:10.1111/DOM.13120.
- Halawi H, Khemani D, Eckert D, O’Neill J, Kadouh H, Grothe K, Clark MM, Burton DD, Vella A, Acosta A, Zinsmeister AR, Camilleri M. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-9; DOI:10.1016/S2468-1253(17)30285-6.
- Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, Burton DD, Busciglio I, Harmsen WS, Vella A, Acosta A, Camilleri M. Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial. Obesity. 2022;30(8):1608-20; DOI:10.1002/OBY.23481.
- Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050-68; DOI:10.7150/IJBS.59965.
- Wang T, Ding J, Cheng X, Yang Q, Hu P. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease. Front Pharmacol. 2024;15:1396656; DOI:10.3389/fphar.2024.1396656.
- Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, Rotstein OD, Butler J, Hess DA, Verma S. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am. J. Physiol. Heart Circ. Physiol. 2024;326(5):H1159-76; DOI:10.1152/AJPHEART.00574.2023.
- Bonfioli GB, Rodella L, Metra M, Vizzardi E. GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction. Heart Fail Rev. 2024;30(1):131-6; DOI:10.1007/s10741-024-10450-6.
- Xie D, Li Y, Xu M, Zhao X, Chen M. Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):200; DOI:10.1186/s12933-022-01634-1.
- Luna-Marco C, de Maran on AM, Hermo-Argibay A, Rodriguez-Hernandez Y, Hermenejildo J, Fernandez-Reyes M, Apostolova N, Vila J, Sola E, Morillas C, Rovira-Llopis S, Rocha M, Victor VM. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol. 2023;66:102849; DOI:10.1016/J.REDOX.2023.102849.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32; DOI:10.1056/NEJMoa2307563.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller D V., Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-84; DOI:10.1056/NEJMoa2306963.
- Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller D V., Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394-407; DOI:10.1056/NEJMoa2313917.
- Chen J, Cooper ME, Coughlan MT. Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists. Diabetes Metab. 2025;51(3):101641; DOI:10.1016/j.diabet.2025.101641.
- Bae JH. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J. 2025;49(3):386-402; DOI:10.4093/dmj.2025.0220.
- Vauvert A, Hviid R, Charlotte X, Sørensen M. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am J Physiol Renal Physiol. 2020;318:443-54; DOI:10.1152/ajprenal.00280.2019.
- Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front Pharmacol. 2020;11:967; DOI:10.3389/fphar.2020.00967.
- Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965-78; DOI:10.1007/s00125-010-2028-x.
- Yang S, Lin C, Zhuo X, Wang J, Rao S, Xu W, Cheng Y, Yang L. Glucagon--like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway. Am J Physiol Endocrinol Metab. 2020;319(6):E1019-30; DOI:10.1152/ajpendo.00195.2019.
- Lee B, Holstein-Rathlou NH, Sosnovtseva O, Sørensen CM. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemo-dynamics the key point? Am J Physiol Cell Physiol. 2023;325:C243-56; DOI:10.1152/ajpcell.00147.2023.
- Battistoni A, Piras L, Tartaglia N, Carrano FM, De Vitis C, Barbato E. Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection. Front Med. 2025;12:1669685; DOI:10.3389/fmed.2025.1669685.
- Cheng CK, Luo JY, Lau CW, Cho WC shing, Ng CF, Ma RCW, Tian XY, Huang Y. A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction. Acta Pharmacol Sin. 2021;42(10):1598-609; DOI:10.1038/s41401-020-00589-x.
- Li Y, Chen Y, Zhang H, Chen W, Pan Y. Liraglutide Ameliorates Renal Endothelial Dysfunction in Diabetic Rats Through the Inhibition of the Dll4/Notch2 Pathway. Diabetes Metab Syndr Obes. 2024;17:4091-104; DOI:10.2147/DMSO.S492252.
- Hinrichs GR, Hovind P, Asmar A. The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight. Am J Physiol Cell Physiol. 2024;326(2):C567-72; DOI:10.1152/ajpcell.00476.2023.
- Tonneijck L, Muskiet MHA, Smits MM, Van Bommel EJ, Heerspink HJL, Van Raalte DH, Joles JA. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023-39; DOI:10.1681/ASN.2016060666.
- Shi JX, Huang Q. Glucagon-like peptide-1 protects mouse podocytes against high glucose-induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro. Mol Med Rep. 2018;18(2):1789-97; DOI:10.3892/mmr.2018.9085.
- Lučić I, Vojković M, Milković L. The AMPK/NRF2/FOXO Axis in CKD— Molecular and Clinical Perspectives. Antioxidants. 2026;15(4):409; DOI:10.3390/antiox15040409.
- Stanigut AM, Tuta L, Pana C, Alexandrescu L, Suceveanu A, Blebea NM, Vacaroiu IA. Autophagy and Mitophagy in Diabetic Kidney Disease—A Literature Review. Int J Mol Sci. 2025;26(2):806; DOI:10.3390/ijms26020806.
- Huang L, Lin T, Shi M, Wu P. Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2024;327(4):R410-22; DOI:10.1152/ajpregu.00083.2024.
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21; DOI:10.1056/NEJMOA2403347.
- Jansz TT, McGovern AP, Young KG, Dinsdale MM, Cardoso P, Shields BM, Hattersley AT, Jones AG, Pearson ER, Bingham C, Oram RA, Dennis JM. Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data. Lancet Prim Care. 2026;2(4):100139; DOI:10.1016/j.lanprc.2026.100139.
- Gandhi A, Parhizgar A. GLP-1 receptor agonists in Alzheimer’s and Parkinson’s disease: endocrine pathways, clinical evidence, and future directions. Front Endocrinol (Lausanne). 2025;16:1708565; DOI:10.3389/fendo.2025.1708565.
- Grieco M, Giorgi A, Gentile MC, d’Erme M, Morano S, Maras B, Filardi T. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019;13:1112; DOI:10.3389/fnins.2019.01112.
- Li S, Huang N, Wang M, Huang W, Shi J, Luo Y, Huang J. GLP-1R as a potential link between diabetes and Alzheimer’s disease. Front Aging Neurosci. 2025;17:1601602; DOI:10.3389/fnagi.2025.1601602.
- Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108; DOI:10.3389/fnagi.2016.00108.
- Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. The Lancet. 2017;390(10103):1664-75; DOI:10.1016/S0140-6736(17)31585-4.
- Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet. 2025;405(10479):627-36; DOI:10.1016/S0140-6736(24)02808-3.
- Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrie re N, Catala H, Charif M, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Geny C, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O. Trial of Lixisenatide in Early Parkinson’s Disease. N Engl J Med. 2024;390(13):1176-85; DOI:10.1056/NEJMoa2312323.
- Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2021;14:614884; DOI:10.3389/fnbeh.2020.614884.
- Amorim Moreira Alves G, Teranishi M, Teixeira de Castro Gonçalves Ortega AC, James F, Perera Molligoda Arachchige AS. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. Med Sci. 2025;13(3):136; DOI:10.3390/medsci13030136.
- Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AMØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PMD, Gillum MP, Jørgensen NR, Bergmann ML, Poulsen HE, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollsta dt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863; DOI:10.1172/jci.insight.159863.
- Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405; DOI:10.1001/jamapsychiatry.2024.4789.
- Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026;136(4):e194740; DOI:10.1172/JCI194740.
- Huang KP, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, Hanchak ND, Patel N, Gbenou YSK, Adriaenssens AE, Bolding KA, Alhadeff AL. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632(8025):585-93; DOI:10.1038/s41586-024-07685-6.
- Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8(5):e70113; DOI:10.1002/edm2.70113.
- He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-9; DOI:10.1001/jamainternmed.2022.0338.
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jo dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44; DOI:10.1056/NEJMoa1607141.
- Badve S V., Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15-28; DOI:10.1016/S2213-8587(24)00271-7.
- Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. J Clin Invest. 2025;135(21):e194751; DOI:10.1172/JCI194751.
- West J, Li M, Wong S, Le GH, Teopiz KM, Valentino K, Dri CE, McIntyre RS. Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. Neurol Ther. 2025;14(4):1157; DOI:10.1007/s40120-025-00724-y.
- Chiang CH, Jaroenlapnopparat A, Colak SC, Yu CC, Xanthavanij N, Wang TH, See XY, Lo SW, Ko A, Chang YC, Song J, Hsia YP, Chiang CH. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025;169(6):1268-81; DOI:10.1053/j.gastro.2025.06.003.
- Silverii GA, Marinelli C, Mannucci E, Rotella F. Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(6):2505-8; DOI:10.1111/dom.15538.
DOI: https://doi.org/10.2478/acb-2026-0005 | Journal eISSN: 2544-3577 (formerly 2080-2218)
Language: English
Page range: 40 - 52
Submitted on: May 12, 2026
Accepted on: Jun 23, 2026
Published on: Jul 20, 2026
Published by: Foundation for Cell Biology and Molecular Biology
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Mateusz Kurowski, Katarzyna Rekiel, Aleksandra Marcinkowska, Oskar Ratajczyk, Piotr Urbanowicz, Stanisław Iwankiewicz, Wojciech Grzelczak, Zuzanna Kaz mierczak, published by Foundation for Cell Biology and Molecular Biology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.